[1]Deng Y, Chen Q, Guo C, et al. Comprehensive single-cell atlas of colorectal neuroendocrine tumors with liver metastases: unraveling tumor microenvironment heterogeneity between primary lesions and metastases. Mol Cancer. 2025;24(1):28. Published 2025 Jan 21. doi:10.1186/s12943-025-02231-y
[2]Jagannath P, Chhabra D, Shrikhande S, et al. Surgical treatment of liver metastases in neuroendocrine neoplasms. Int J Hepatol. 2012;2012: 782672.
[3]Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005 May;241(5):776–83; discussion 783–5
[4]Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul;17(7):883-895.
[5]Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016 Jun 30;374(26):2542-52.
[6]Albertelli M, Dotto A, Nista F, et al. "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord. 2021 Sep;22(3):615-636.
[7]Lu M, Zhang P, Zhang Y, et al. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clin Cancer Res. 2020 May 15;26(10):2337-2345.
[8]Chu Y, Dai E, Li Y, et al. Pancancer T-cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023 Jun;29(6):1550-1562.
[9]Tang F, Li J, Qi L, et al. A pan-cancer single-cell panorama of human natural killer cells. Cell. 2023 Sep 14;186(19):4235-4251.e20.
[10]Yang Y, Chen X, Pan J, et al. Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes. Cell. 2024 Aug 22;187(17):4790-4811.e22.